Epinephrine Autoinjector Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The epinephrine autoinjector market is segmented by Dosage (0.15 mg, 0.30 mg, and 0.50 mg), Age-group (0 to 6 Years, 6 to 12 Years, and over 12 Years), End-User (Hospitals, Clinics, and Home-based), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD Million) for the above segments.

Epinephrine Autoinjector Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Epinephrine Autoinjector Industry Overview

The epinephrine autoinjector market is consolidated in nature with the presence of a few established vendors holding the majority of the shares and operating globally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known, including Adamis Pharmaceuticals Corporation, Alk-Abello A/S, Amneal Pharmaceuticals, Mylan NV, Antares Pharma, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Sanofi SA, Novartis International AG, among others.

Epinephrine Autoinjector Market Leaders

  1. ALK-Abelló A/S

  2. Amneal Pharmaceuticals, Inc.

  3. Antares Pharma, Inc.

  4. Pfizer Inc.

  5. Teva Pharmaceutical Industries Ltd.

  6. *Disclaimer: Major Players sorted in no particular order
Epinephrine Autoinjector Market Concentration